Who
Eric J. Ende
Director
Company insider
Files Form 4 as: Director, Avadel Pharmaceuticals; Director, Matinas Biopharma Holdings; Director, NeuBase Therapeutics; Director, Progenics Pharmaceuticals; Director, Genzyme.
In numbers
- Trades disclosed
- 77
- Buys
- 13
- Sells
- 0
- Bought
- $1.1M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 16 Jun 2010
- Last trade
- 12 Feb 2026
- Last filed
- 12 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 12 Feb 2026 | Avadel PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $4.6M219,905 at $21.00 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,057 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —60,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —8,057 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —42,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —42,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —42,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —33,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —42,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —42,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —42,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —33,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticals | SEC FORM 4 Code D | $4.6M219,905 at $21.00 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,000 | filing |
| 29 Jul 2025filed 31 Jul 2025 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | Avadel Pharmaceuticals | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
News
Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Shares Shorted: Short Interest Down 87.3% in SeptemberMTNB · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Eric J. Ende; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.